Depressive severity is typically measured according to total scores on questionnaires that include a diverse range of symptoms despite convincing evidence that depression is not a unitary construct. When evaluated according to aggregate measurements, treatment efficacy is generally modest and differences in efficacy between antidepressant therapies are small.
chine learning of clinical data, 8 performance in predicting outcomes remains modest. 9, 10 Heterogeneity among depressive symptoms may impede the evaluation of treatments for depression. 11, 12 For example, treatment efficacy for one group of symptoms may be masked by a lack of efficacy for other symptoms, potentially explaining mixed results from large comparative efficacy meta-analyses. 4, 13 For example, selective serotonin reuptake inhibitors are generally effective in reducing low mood 14 relative to other symptoms. However, evaluating outcomes on an individual symptom level may be cumbersome since clinicians would need to remember treatment guidelines specific to each symptom. Although symptoms might be grouped based on clinical experience (eg, "melancholic depression") 15 or the use of rating subscales (eg, Hamilton Rating Scale for Depression-7), novel associations might be overlooked by this process. Statistical methods enable one to categorize depressive symptoms into subcomponents. For example, one study showed that nortriptyline hydrochloride is more effective than escitalopram in treating a neurovegetative symptom dimension, but escitalopram was more effective in treating mood and cognitive symptom dimensions. 16 However, traditional statistical approaches have some shortcomings. Factor analyses, for example, may generate complicated combinations of symptoms within particular dimensions. 16 These analyses also may be susceptible to experimenter bias since one often has to choose the desired number of clusters or components in the data, as in k means clustering. 17 By contrast, hierarchical clustering is an easy-to-visualize, deterministic method in which each symptom is assigned to a single cluster (ie, not loading across multiple clusters) without prespecifying the desired the number of clusters.
In this study, we explored the efficacy and predictability of antidepressant therapies in treating specific groups of symptoms (eMethods [which includes eTables 1-10 of various analyses] and eFigure 1 in the Supplement). We used an unsupervised machine-learning approach (hierarchical clustering) to establish a data-driven grouping of baseline symptoms. The clustering method was applied to patients from a large multisite trial of depression and a replication sample from an independent clinical trial with similar inclusion criteria. Next, we reanalyzed treatment outcomes for 9 archival clinical trials ( Table 1 ) according to the severity of each symptom cluster (rather than total severity) to determine whether symptom clusters are equally responsive to antidepressant treatments and whether certain drugs and doses are more effective than others. Finally, we used supervised machine learning to predict outcomes specific to each cluster of symptoms since there may be good clinical or biological indicators of changes in some symptoms that do not correlate strongly with changes in other features of depression.
Methods

Clinical Trial Data
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial is the largest prospective, randomized clinical trial of outpatients with major depressive disorder.
18-21 Eligible participants were treatment-seeking outpatients with a primary clinical (DSM-IV) diagnosis of nonpsychotic major depressive disorder scored 14 or higher on the 17-item Hamilton Depression (HAM-D) rating scale, were aged 18 to 75 years, and were recruited from primary and psychiatric care settings in the United States from June 2001 to April 2004. 19 We focused on the first treatment stage consisting of a 12-week course of citalopram hydrobromide. The present study was conducted from October 28, 2014 , to May 19, 2016 . It was approved by the Yale University Human Subjects Committee, with a waiver of informed consent. The Combining Medications to Enhance Depression Outcomes (CO-MED) trial was a multisite, single-blind, randomized clinical trial comparing the efficacy of medication combinations in the treatment of unipolar major depressive disorder. 22, 23 Eligible patients were aged 18 to 75 years, had a primary DSM-IV-based diagnosis of nonpsychotic major depressive disorder, had recurrent or chronic depression (current episode ≥2 years), scored 16 or higher on the 17-item HAM-D rating scale, and enrolled participants between March 2008 and February 2009. Patients were randomly allocated (1:1:1) to escitalopram plus placebo (monotherapy), escitalopram plus bupropion hydrochloride, or venlafaxine hydrochloride plus mirtazapine. We also analyzed all arms from 7 randomized, multicenter, double-blind, placebo-controlled, and active comparatorcontrolled clinical trials of duloxetine for major depressive disorder (Table 1) . Four different protocols were used for these
Symptom Clustering
Rating scales in depression include a diverse range of symptoms. We applied a data-driven approach to identify groups of symptoms within depression rating scales. Higher scores on the rating scales indicate more severe symptoms. Hierarchical clustering shows structure in data without making assumptions about the number of clusters that are present in the data and gives a deterministic solution. We applied agglomerative (bottom-up) hierarchical clustering to the QIDS-SR checklist completed at baseline in STAR*D by 4017 patients and replicated the analysis using baseline QIDS-SR data from CO-MED (n = 640) and the baseline HAM-D scale that was also collected on 4039 patients in STAR*D. We conducted multiple sensitivity analyses using alternative approaches (eFigures 3-9 and eTables 1-3 in the Supplement). 
Evaluation of Treatment Outcomes Treatment Efficacy
We analyzed the full intent-to-treat samples in all trials using linear mixed-effects regression models (STAR*D, 4041; CO-MED, 665; and other trials, 2515) . The dependent measure was mean within-cluster severity: for each patient at each time point, we calculated the mean symptom severity within each cluster. Fixed effects included symptom cluster, time (logtransformed weeks), treatment regimen, and all 2-and 3-way interaction effects. We included a separate random intercept and slope for each symptom cluster with unstructured variance-covariance of the random effects within subject based on improvements in the Schwarz-Bayesian information criterion.
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False-discovery rate-adjusted 34 P values were used to determine statistical significance for post hoc comparisons by cluster and drug within each mixed-model analysis.
One model was used to analyze QIDS-SR-based clusters across STAR*D and CO-MED, and another model was used to analyze HAM-D-based clusters for the 7 other placebocontrolled trials. In the HAM-D model, we also included the main effect of the trial to control for potential systematic differences among trials. Preliminary analyses of the 4 duloxetine doses in each cluster indicated that 120-mg/d and 80-mg/d dosages were not significantly different from each other but differed from the lower doses and placebo (eResults and eFigure 10 in the Supplement). The 60-mg/d and 40-mg/d duloxetine dosages were similar to each other and nearly indistinguishable from placebo. We therefore grouped cohorts into high-dose duloxetine (80-120 mg/d) and low-dose duloxetine (40-60 mg/d).
Outcome Predictability
We used a recently developed statistical modeling pipeline 8 to predict treatment outcomes specific to each symptom cluster using information available at baseline. We extracted 164 items, including demographics, medical and psychiatric histories, and specific symptom items that were used as predictor variables (eTable 10 in the Supplement). Penalized logistic regression (elastic net 35, 36 ) was then used to identify the 25 variables that best predicted each cluster separately. These variables were then used to train machine-learning algorithms (gradient boosting machines 37, 38 ), resulting in a separate model for each symptom cluster, with each using 25 predictor variables. Predictability was measured as the percentage of variance explained in final cluster scores (ie, R 2 ) using 5 repeats of 10-fold crossvalidation. The statistical significance of each model was assessed using a permutation test (eMethods in the Supplement). We trained models on patients with complete baseline data for whom a severity score was recorded after 12 or more weeks of treatment (n = 1962) to ensure adequate treatment duration. To externally validate our predictive models, they were applied without modification to predict final cluster scores in CO-MED treatment completers. Here, statistical significance was measured by a P value calculated for Pearson correlations between predicted outcomes and observed outcomes in each treatment group of CO-MED. We did not have comparable predictor data in the duloxetine trials; thus, predictive analyses were conducted only for STAR*D and CO-MED. For significance, permutation-based tests used an α level of .01, mixed-effects regressions used a false-discovery rate correction and then an α level of .05, and Pearson correlations used an α level of .05. Predictive and clustering analyses were implemented in R, version 3.2.3 (R Foundation). Efficacy analyses were conducted using SAS, version 9.4 (proc mixed) (SAS Institute).
Results
In 2 independent trials, we identified the same clustering of symptoms in the QIDS-SR checklist, consisting of core emotional, sleep (insomnia), and atypical symptoms ( Figure 1A and B). A similar clustering solution was also found for the HAM-D scale checklist ( Figure 1C ). The clustering solution was robust across a number of sensitivity analyses using different parameters, time points, and approaches (eFigures 3-9 and eTables 1-3intheSupplement).
Efficacy Analyses
Treatment efficacy was measured according to the rate of symptom improvement over time (ie, steeper symptom trajectories are better, as shown in Figure 2 ). No antidepressant treatment worked equally well across all 3 symptom clusters.
As shown in Figure 2A , when measured according to the QIDS-SR, trajectories were significantly better for core emotional symptoms than for either sleep symptoms or atypical symptoms for citalopram, escitalopram with placebo, and escitalopram with bupropion (all β>0.079; all false-discovery rate corrected P < .001). Sleep trajectories were also better than atypical trajectories for these 3 treatments (all β>0.099; all P ≤ .001). As shown in Figure 2B , when measured according to the HAM-D rating scale, a similar pattern was observed. Core emotional trajectories were better than sleep and atypical trajectories for all treatments (all β>0.12; all P ≤ .001). Sleep trajectories were also better than atypical trajectories for lowdose duloxetine and escitalopram (all β>0.080; all P ≤ .001). All slope contrast estimates, SEs, 95% CIs, and P values are included in eTables 4 and 5 in the Supplement.
To interpret the magnitude of differences between drugs, we calculated an effect size (ES), measured in raw rating scale points, that reflects the difference between treatments in reducing the overall severity of a symptom cluster (ie, we multiplied slope contrasts by the natural log of treatment duration and then by the number of symptoms in each cluster). For example, in this study, high-dose duloxetine was significantly better than escitalopram in treating atypical symptoms, such that a patient's total improvement in atypical severity was a mean of 1.9 HAM-D points greater with highdose duloxetine than escitalopram (ES, 1.9; 95% CI, 1.4-2.3; false-discovery rate corrected P < .001).
For each symptom cluster, there were significant differences in efficacy between treatments ( Figure 2 ). Combined escitalopram and bupropion treatment was significantly more effective in treating core emotional symptoms than citalopram (ES, 0.7 QIDS-SR points; 95% CI, 0.2 to 1.3; P = .03). For sleep/insomnia symptoms, venlafaxine with mirtazapine outperformed citalopram (ES, 1.4; 95% CI, 1.0 to 1.8; P < .001). For
Predictive Analyses
Within STAR*D, although all models performed significantly above chance (all P < .01), we observed substantial variability in the predictability of outcomes for each cluster ( Table 2 and eTable 8 in the Supplement). The sleep symptom cluster was the most predictable (R 2 = 19.6%; SD, 5.0%; P < .01) and substantially more predictable than core symptoms (R 2 = 14.5%; SD, 4.6%; P < .01) and atypical symptoms (R 2 = 15.1%; SD, 5.3%; P < .01). The observed range in cluster predictability (R 2 difference, 5.1%) was also significantly larger than any range observed during permutation testing (mean [SD] range, 0.56% [0.50%]; P < .01). We inspected the best predictive baseline variables for each model separately, highlighting those identified as predictive for 1 cluster but not others (ie, specific predictors) ( Table 2) . Baseline HAM-D scale severity was a top predictor of core emotional outcomes but not any of the other 3 clusters. Baseline atypical symptom severity and hypersomnia predicted atypical outcomes; baseline sleep cluster severity and early-morning insomnia predicted sleep outcomes. We then applied the best-performing models, without modification, to predict outcomes for each cluster in the 3 treatment groups of CO-MED ( Figure 3) . Performance was statistically above chance, although clinically modest, for predicting core emotional outcomes in the escitalopram monotherapy arm (r 149 = 0.18; P = .03) and the venlafaxine-mirtazapine arm (r 138 =0.17;P = .04). Performance was above chance predicting sleep outcomes in the escitalopram-bupropion arm (r 132 = 0.36; P < .001).
Clinical Decision Support Tool
To help translate these findings into clinical practice, we based a clinical decision support tool on these findings. It is implemented as a brief questionnaire that can be accessed from any web browser and returns results in real time (https://www .spring.care/spring-assessment).
Discussion
Using a data-driven approach, we identified 3 symptom clusters within the QIDS-SR checklist. We replicated our clustering solution in an independent trial cohort (CO-MED) and found it to be robust across different parameters and time points and consistent with other statistical approaches. No antidepressant was equally effective for all 3 symptom clusters, and, for each symptom cluster, there were significant differences in treatment efficacy between drugs. Antidepressants in general worked best in treating core emotional and sleep symptoms and were less effective in treating atypical symptoms. The magnitude of these differences suggests that selecting the best drug for a given cluster may have a bigger benefit than that 4, 13 our results at the symptom cluster level indicate substantial differences between drugs both within and across putative antidepressant classes. Moving forward, we must establish how improvements in a given cluster relate to quality of life, keeping in mind that medication tolerability remains an important clinical concern (as reviewed elsewhere 4, 13 ).
The approach outlined in this article may have implications for the drug approval process. United States Food and Drug Administration and European Medicines Association approval are currently determined in trials that use aggregate scores on severity measures to enroll patients or measure outcomes. Although some trials have used a specific symptom as an outcome (eg, depressed mood), our findings indicate that medications might be developed for specific clusters of symptoms, as they appear to respond differentially to antidepressant medications. Symptom clusters may also enable drug testing in smaller but more informative populations with a more consistent phenotype. This approach is consistent with the National Institute of Mental Health Research Domain Criteria 40 -symptom clusters or dimensions might have distinctive underlying neural circuitry and signaling mechanisms-and paves the way for developing treatments that target and biomarkers that predict changes in specific clusters of symptoms.
Further clinical research will determine whether these clusters generalize to other cohorts and reflect good candidates for a true symptom structure in major depression. 41, 42 The present cluster structure resembles that of other scales in other large samples of patients with depression, 1-4 although a recent review concluded that the debate is not over. 41 These studies and ours are largely consistent in isolating symptoms of insomnia, a core group of symptoms that includes low mood, anhedonia, and low self-worth. However, direct comparisons are impeded by the use of many different rating scales in depression. 42 Our data-driven approach offers some novel symptom groupings relative to previous approaches. For instance, our emotional cluster resembled the HRSD-7 subscale but never included a suicide item, and when scored according to the HAM-D scale, the HRSD-7 energy/ fatigability item clustered with insomnia symptoms rather than emotional symptoms. There were slight differences between the QIDS-SR and HAM-D scale results. In the HAM-D scale, the emotional cluster included an anxiety item, whereas in the QIDS-SR scale, the same cluster included low energy and concentration. The energy/concentration item falls in the sleep cluster for the HAM-D scale. This data-driven approach may have identified a set of symptoms in the emotional presentation of depression that may have neural circuit correlates that are more cohesive than either the DSM criteria or theorydriven clusters, such as the Bech/Maier scales, which have not yet produced meaningful signatures on neural circuits or treatment response prediction. 10, 43 Finally, the atypical cluster contains items that are not considered atypical items in the DSM, so conclusions about broader atypical symptoms should not be drawn from the naming of this cluster.
Limitations
This study has some limitations. First, there was a high degree of study heterogeneity. Two rating scales (clinicianrated HAM-D vs self-rated QIDS-SR) and treatment durations (8 vs 12 weeks) were used. The studies used a mixture of fixedand variable-dosage protocols and had differences in blinding (STAR*D was unblinded, CO-MED was single-blind, and all other trials were double-blind). The consistency of these findings from 7000 patients from these heterogeneous studies suggests that the findings should generalize. However, study differences precluded direct comparisons using all available data, and study selection based on data availability may be a source of bias. 44 Our inclusion of placebo-controlled duloxetine trials was critical for considering the pattern of cluster response trajectories for placebo and determining whether trajectories were better with drug treatment than placebo. Ideally, behavioral interventions might be focused on atypical symptoms that are generally less responsive to antidepressants or combined with other focused interventions for specific/residual symptoms (eg, modafinil for energy/fatigue, zolpidem for insomnia). Finally, group-level differences do not translate to individual patient differences in a simple manner 45 ; therefore, further research is needed to test whether the web tool is accurate and effective in real-world practice. Larger limitations surround the interpretation of current predictive analyses (eTable 9, eFigure 11, and eDiscussion in the Supplement). Generalizability of our original pipeline was poor. Alternative analytic strategies may be more effective (eFigure 10 in the Supplement). This limitation highlights the importance of externally validating predictive tools rather than relying on metrics based on the discovery sample. 8 Because it is impractical for each model to require 25 different items, we must identify a more limited group of predictor variables to use cluster-specific tools in the clinic.
Conclusions
Clusters of symptoms are detectable in 2 common depression rating scales, and these symptom clusters vary in their responsiveness to different antidepressant treatments. These patterns may offer clinicians evidence for tailoring antidepressant selection according to the symptoms that a specific patient is experiencing immediately-almost doubling the expected effect size of a treatment. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Investigators seeking access to the data can visit http://www.nimh.nih.gov/funding/clinical-trials-forresearchers/datasets/nimh-procedures-for-requesting-data-sets.shtml.
All participants provided written informed consent at enrollment, with consent and study protocols approved by institutional review boards at each participating institution.
1,2
Data for other trials were provided to RG and JHK by Eli Lilly and Company (CCGO Agreement #2793, November 21st 2007) for use in trajectory-based analysis of treatment outcomes. Four different protocols were used for these studies (HMAT, HMAY, HMAQ and HMCR). Part A and B reflect trials run in parallel following the same protocol. Pooling of data from these trials was anticipated during study design. All studies incorporated double-blind, variable duration placebo lead-in periods to blind patients and investigators to the start of active therapy. Safety and efficacy results from these studies have been published previously as individual study reports [3] [4] [5] [6] and summarized as pooled analyses of safety 7 and efficacy 8 . Studies HMAQ A and B, HMAT A and B, and HMAY A and B were conducted before clinical trial registration was necessary. Study HMCR is registered at ClinicalTrials.gov (NCT00073411). More details can be found in prior publications on these data, e.g. Gueorguieva, Mallinckrodt & Krystal (2011, Archives of General Psychiatry) .
Dataset description
STAR*D and COMED were both designed to be as representative of the general population as possible, using broad inclusion criteria and few exclusion criteria. Full details of these criteria can be found in the protocol files included in the dataset. Although criteria were largely similar, some criteria were different (e.g. STAR*D patients had to have a HAM-D score over 14, for COMED it was 16 or more). The criteria were as follows: STAR*D Inclusion Criteria:  Outpatients with nonpsychotic MDD.  A score of >14 on the HAM-D17.  Outpatients for whom antidepressant treatment is deemed appropriate by the treating clinician.  Age range: 18-75.  Participants with suicidal ideation are eligible, as long as outpatient treatment is deemed safe by the clinician (i.e., inpatient care is not called for clinically).  Participants who have most GMCs are eligible. Participants whose GMCs could conceivably be physiologically causing their depressive symptoms will receive treatment as usual for their GMCs as well as protocol Level 1 treatment for their MDD. We anticipate that during Level 1 most medical GMCs will be treated so that if depressive symptoms persist after treatment for the GMC and after CIT for the depression, participants with these conditions are eligible for randomization into Level 2.
Exclusion Criteria:  Participants must not have an established, well-documented history of nonresponse or clear intolerability in the current major depressive episode to one or more treatments required by the protocol, delivered at an adequate dose (e.g., >40mg/d of citalopram for at least 6 weeks or > 16 sessions of CT).  Participants with a lifetime history of bipolar disorder (BPD I, II, and NOS), schizophrenia, schizoaffective disorder, or MDD with psychotic features.  Participants who currently suffer from a primary diagnosis of anorexia nervosa, bulimia nervosa, or OCD.  Participants with severe, unstable concurrent psychiatric conditions likely to require hospitalization within six months from study entry (e.g., participants with severe alcohol dependence with a history of recent admissions aimed at detoxification).  Participants with substance dependence disorders who require inpatient detoxification. Participants with active substance abuse or dependence disorders who enter the study will receive whatever care is routine at their clinical site (e.g., substance abuse counseling) for these conditions.  Participants with certain concurrent psychiatric or medical conditions that are relative or absolute contraindications to the use of more than one treatment option within the protocol so that randomization to any of the strategies or substrategies within each level (Levels 2, 3, and 4) is not possible. Participants with certain concurrent psychiatric or medical conditions that are relative or absolute contraindications to the use of one or more of the treatment options within the protocol and with the possibility of randomization to at least one of the strategies or substrategies within each level (Levels 2, 3, and 4) may enter the study, as long as the contraindication is noted and the strategy/substrategy involving the contraindicated treatment option is dropped.  (Participants taking any concomitant nonpsychotropic medications (save for anxiolytics and sedative hypnotics) may enter the study as long as their clinician determines that antidepressant treatments in the protocol are appropriate and safe. When there is a known association between the concomitant medication and depression, as suggested by the AHCPR guidelines, we will encourage clinicians to substitute, whenever possible, the concomitant medication with another that is not associated with depression before study entry or, when the latter is not feasible, during Level 1.  Participants already receiving a targeted psychotherapy aimed at their depression may not enter the study. Those who have not responded to such psychotherapy and subsequently terminated it prior to study enrollment or those who are receiving counseling or therapy for other problems (e.g., marital counseling to address marital discord; psychodynamic treatment of character issues) may enter the study.  Participants who are pregnant or who will be trying to become pregnant within the subsequent 6-9 months. antipsychotic medications, anticonvulsant medications (gabapentin, pregabalin, and topiramate are allowed for pain as determined by the treating clinician), mood stabilizers, or central nervous system stimulants.  Antidepressant medication used for the treatment of depression or other purposes such as smoking cessation or pain are excluded since these agents may interfere with the testing of the major hypotheses under study (low dose trazodone is allowed for insomnia, < 200 mg/day).  Uncontrolled narrow angle glaucoma  Patients taking thyroid medication for hypothyroidism may be included only if they have been stable for 3 months  Patients using agents within the prior 7 days that are potential augmenting agents (e. 2) Clustering analysis is replicated on independent sample (COMED trial). 3) Trial outcomes are re-analysed for 9 clinical trials according to each symptom cluster. 4) Outcomes specific to each symptom cluster are predicted using machine learning, by training models STAR*D (using cross-validation), and then validating the models in COMED.
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Sample selection
For clustering analyses, we included all baseline measurements available. For the QIDS-SR16: in STAR*D this was 4,017, in COMED it was 640. For the HAM-D: in STAR*D this was 4,039.
For mixed-effects analyses, we used the full intent to treat samples for each treatment cohort (main manuscript, table 1).
For predictive analyses, in order to allow the model to extract some relationship between the inputs and treatment response, we only included patients for whom a severity score was recorded after 12 or more weeks of treatment (N = 1,962) . In a previous study using the same data and similar analytic pipeline 9 , conclusions remained the same for predictive analyses of the full STAR*D sample, including patients who dropped out of the trial after week 0. For validation in COMED, outcomes were available at 12-or 16-weeks as follows: escitalopram plus placebo n=151; escitalopram plus bupropion n=134, venlafaxine plus mirtazapine n=140.
Clustering Analysis
Agglomerative hierarchical clustering analysis was conducted on baseline QIDS-SR data for both trials. Baseline data were available in STAR*D for 4,017 patients, and in COMED for 640 patients. This procedure groups items in the QIDS checklist according to the similarity of their responses across patients. With this procedure, groups of symptoms that merge at high values relative to the merge points of their subgroups are considered candidates for natural clusters 10 . Symptom similarity was defined by the Manhattan distance (a.k.a. "cityblock" distance) using the stats::dist function in R. Hierarchical clustering was then conducted on this dissimilarity matrix using the stats::hclust function in R, according to the Ward.D2 agglomeration method. The resulting dendrogram was then pruned using the dynamicTreeCut::cutreeDynamic function 11 in R, using the hybrid method, and the least restrictive minimum cluster size (i.e. minimum cluster size = 1). A permutationbased test (SIMPROF procedure 12 ) was used to ensure that the clusters that we derived were statistically reliable (i.e. permutation-based cut points had to be lower than or equal to the cut points determined through dynamic tree cutting), with 100 permutations.
Similarity profiling 12 , is a method of exploratory data analysis that can be used to objectively identify the members of "real" groups present in the results returned from hierarchical agglomerative clustering . First, a similarity profile is constructed from a matrix in which patients are rows and each column represents a symptom in a depressive checklist. Any appropriate resemblance measure can be used (we used Manhattan distance). The lower tridiagonal of the similarity matrix is then converted to a vector, and sorted by magnitude. This sorted list of similarities provides a profile of the structure underlying the observed data. An iterative permutation procedure, based on randomly shuffling the original raw data, is then used to generate a mean permuted similarity profile, which represents the profile expected under the null model. The congruence between the observed similarity profile and the null model is measured using the pi statistic, as the sum of the absolute differences between corresponding elements of the two profiles. The pi statistic is then assessed via a permutation test, if it is statistically significant the null hypothesis that no multivariate structure exists within the data is rejected at the appropriate alpha level (0.05). In other words, similarity profile analysis examines whether the similarities observed in the data are smaller and/or larger than those expected by chance. This is a compelling alternative to more traditional methods that rely on subjective assessment to determine appropriate cutpoints because similarity profiling identifies the point at which clusters become statistically homogenous, ensuring that although there may be residual heterogeneity within a cluster, the cluster as a whole is still meaningfully different to all other clusters at a given cut level.
HAM-D clustering
Seven placebo-controlled phase 3 trials of duloxetine measured outcomes according to the HAM-D scale rather than the QIDS. Fortunately, in STAR*D, a HAM-D checklist was also completed at baseline for 4,039 patients (although not longitudinally). In order to conduct comparable symptom-cluster efficacy analyses of these additional datasets that used HAM-D longitudinally, we conducted a clustering analysis on the HAM-D checklist that was completed at baseline in STAR*D. As before, weight and appetite items were excluded. In addition, as described in the main manuscript, the HAM-D
Further information about open-source and other implementations of the method can be found at http://www.marine.usf.edu/user/djones/simprof/simprof.html loss of insight item (e.g. "Denies being ill at all") was also excluded from analysis as it can only be determined by a clinician and has no equivalent construct in the QIDS checklist. Similarity profiling was conducted as before to ensure that any cutpoint used was statistically meaningful. The hybrid dynamic tree cutting procedure was modified slightly, now cutting at 80% of the range between the 5th percentile and the maximum of the joining heights on the dendrogram, to improve comparability of the cut points used across the two checklists. Nonetheless, the tree was still cut substantially higher than the minimum cut points identified through similarity profiling. Figure 1 (main manuscript, lower panel) illustrates the resulting dendrogram for this clustering analysis.
Despite differences in the items used between the two checklists, and scoring ranges for each item, a broadly similar solution was found for the HAM-D as the QIDS. Once again, a cluster of core emotional symptoms emerged, this time with a subdivision between mood/anhedonia and other symptoms in the cluster (irritability, somatic anxiety, feelings/delusions of guilt). The sleep cluster remained largely unchanged, grouping the equivalent insomnia items along with low energy/fatigue. A third cluster again grouped psychomotor agitation/retardation with suicidal thoughts, and now included two further symptoms (reduced libido, hypochondriasis) that are not present in the QIDS checklist. As mentioned in the main manuscript, there were some slight differences between the QIDS and HAM-D results. In the HAM-D, the core emotional cluster included an anxiety item, whereas in the QIDS the same cluster included low energy/concentration. The energy/concentration item falls in the core emotional cluster for the QIDS but falls in the sleep cluster for the HAM-D. It should be noted that, the atypical cluster contains items that are not considered "atypical items" in the DSM, and so conclusions about broader atypical symptoms should not be drawn from the naming of this cluster.
Trajectories for excluded symptoms
As discussed in the main manuscript, weight and appetite symptoms were excluded from the clustering and efficacy analyses. eFigure 2 below illustrates symptom trajectories for the individual excluded weight and appetite symptoms in STAR*D and COMED.
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Predictive Modeling Technical Summary
We used largely the same predictive modeling procedure described in detail in Chekroud et al. (2016, Lancet Psychiatry, appendix) . Some slight changes were made now that all procedures must be done three times (once for each symptom cluster). Specifically, the hyperparameter grid search was now over the following parameter combinations: Elastic net alphas and lambdas ; GBM number of trees , shrinkage , interaction depth , and the number of minimum observations in a terminal node was fixed at 25. In addition, we used 5 repeats of 10-fold CV (i.e. 5x10 CV), rather than 10 in our previous study. Since symptom cluster outcomes were continuous variables, optimal tuning parameters were selected that minimized RMSE, and the GBM used a laplacian distribution (absolute loss) rather than Gaussian.
We extracted all readily available information about patients at baseline that overlapped between the STAR*D and COMED trials. Variables were centered and scaled (stats::scale function in R): for STAR*D using the completer sample; in COMED variables were centered and scaled for each treatment arm separately. Next, a cross-validated (5x10cv) elastic net model was used to identify a group of 25 predictive features in the entire STAR*D completer cohort, based on ranked absolute beta values. The caret package was used in R, as a wrapper for the glmnet and gbm packages. These 25 features were then used to train a GBM to predict symptom cluster outcomes (i.e. the sum-score of symptoms within a cluster). In both cases, optimal hyperparameters were selected through a grid search of the plausible parameter spaces through an RMSE-minimization process. All modeling was done using a parallel backend (R package doMC), restricted to 32 cores. To improve the reproducibility of our results, a seed was set locally (set.seed (1)), and a sequence of random integers (of pre-determined length) was generated and pushed to backend worker nodes for model building during repeated cross-validation. Before each train() call, the seed was reset locally, and all models used the same pre-determined sequence of parallel seeds.
The best model built on the STAR*D completer set was taken without modification and applied to each of the three COMED arms (stats::predict function in R). Relevant descriptions of model performance -including RMSE and R 2 -were determined at each stage. The statistical significance of each model in STAR*D was assessed using a permutation test, for COMED validation it was assessed using a correlation test. For the permutation test: outcomes were shuffled before the modeling pipeline was applied (100 repeats), and the unshuffled R 2 was compared to the distribution of shuffled-R 2 s ( = 0.05). By convention, the minimum possible p-value is thus 1/(number of permutations) 13 , which is 0.01 in this case. For the correlation test, a p-value was calculated for the Pearson correlation between predicted values and observed values.
To examine whether a less sensitive predictive pipeline might be more appropriate for predicting symptom clusters, we conducted exploratory analyses using a simplified analysis pipeline. This pipeline still consisted of two parts, and the first part remained unchanged (i.e.an elastic net to identify 25 variables). However, instead of using a GBM to model the 25 predictors, we instead used a general linear model for model building. Once again, all models performed above chance in STAR*D (all p's<0.01), with broadly comparable R 2 . These GLMs (one for each symptom cluster) were then applied without modification to predict cluster outcomes in each COMED arm. GLMs for all three symptom clusters successfully generalized to predict outcomes for both Escitalopram and Escitalopram + Bupropion (p's<0.044) . Models of atypical (p < 0.001) and sleep (p = 0.045) symptoms also generalized for the Venlafaxine + Mirtazapine arm.
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Supplementary clustering results
A number of sensitivity analyses were conducted to explore the robustness of the clustering solutions, and how they compare to alternative approaches. On the whole the clustering results were robust, even when using different parameters, different time points, and different statistical approaches.
Factor analyses
Traditional exploratory factor analysis with varimax rotation was conducted on the STAR*D sample for comparison with hierarchical clustering results. The factanal function in the stats package in R was used to conduct the analysis, and a parallel analysis was conducted using the parallel function from the nFactors package to determine the appropriate number of factors. The Kaiser rule, parallel analysis, and optimal coordinates, all indicated that three factors was the appropriate number of factors to extract for these data. eTable 1 describes the factor loadings for the three factor solution and eFigure 3 illustrates the resulting scree plot. eTable 1. Factor Loadings for the Three Factor Solution Supp. To understand the influence of correlations amongst latent variables, we ran an additional factor analysis with oblique rotation (R-CMD rotation = "promax"). As described by the factor loadings in eTable2, the oblique rotation resulted in a different factor structure, perhaps with a very slightly lower quality fit (in terms of cumulative variance explained). eTable 2. Factor Loadings (Oblique Rotation)
Supp. 
Clustering analyses
We conducted hierarchical clustering of the baseline QIDS data in STAR*D using a different distance metric (Euclidean distance). The result (eFigure 4) was the same: eFigure 4 -Euclidean distance metric
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We conducted divisive clustering (using the diana package), and recovered a similar solution. The resulting dendrogram is as follows:
We explored whether the clustering results were stable over time, i.e. whether they are only present at baseline, or whether they persist at other points during treatment. With this in mind, we conducted two further clustering analyses (manhattan distance, ward.d2 linkage). In both cases, we found either the exact same or an extremely similar symptom structure, suggesting our findings are robust to this manipulation.
eFigure 5 -Divisive clustering
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(1) To understand how the clustering results would look toward the end of the study, we clustered QIDS responses at the 9 th week of treatment (N=2,215):
(2) We also clustered all available QIDS responses (between 0 and 14.2 weeks), i.e. the long-form data set consisting of 17,489 person-timepoints.
eFigure 6 -Clustering after 9 weeks of treatment When we include all timepoints (which is arguably the most stable/robust approach), we recover the exact same clustering solution as our main finding. When we restrict the data to only observations at week 9, the clustering solution is certainly different but shares a number of key similarities with our primary analysis (i.e. the grouping of sleep/insomnia items [although mid-nocturnal insomnia falls into its own cluster], and suicidal/psychomotor symptoms separating from symptoms of low mood and worthlessness). Admittedly, we also expected to see substantially reduced dimensionality in the clustering solution over the course of treatment (and, anecdotally, we have observed it in other contexts). However, at least in the STAR*D data using this clustering technique, it seems like the original finding is fairly robust to the inclusion of other timepoints (during treatment). One wonders whether changes in complexity/dimensionality might reflect something deeper about the nature of the relationship between treatment and symptoms. For example, the changes in dimensionality at the end of treatment could be the result of one cluster being "knocked down" by treatment. Alternatively, treatments may be distorting the interconnections between certain symptoms, and the behavioural correlates of this process are what bring about the therapeutic response.
Clustering without excluding weight/appetite symptoms eFigure 7 -Clustering data from all time points
As described in the main manuscript, we excluded the two appetite and two weight items from the clustering analysis. For completeness, we also present the clustering solutions that are obtained when all 16 items are included (eFigure 8). In both cases, an identical sleep (insomnia) and core emotional cluster emerged, and these clusters were also found in the 12-item clustering analysis. 
Silhouette analysis
We conducted a silhouette analysis 14 to better understand within-cluster consistency. The silhouette value is a measure of how similar an object is to others within its cluster vs those in other clusters. Values can range from -1 (no similarity at all, or wrong cluster assignment) to 1 (perfect clustering), and values close to 0 indicate that the item is on the border of two natural clusters. Of course, the absolute values observed depends on the context (especially the noise inherent in the data, the number of clusters, etc). With this metric for each item, one can calculate an average silhouette for each cluster, and this value serves as a metric for how tightly grouped all the data are in a single cluster. The results of the analysis are summarized in the silhouette plot 15 below (eFigure 9).
According to the average silhouette metric, the sleep cluster was the least homogenous cluster, and the core emotional cluster was the most homogenous. Although we did not have a strong hypothesis regarding this result, one might interpret it in relation to the fact that sleep/insomnia symptoms might affect a broad number of other symptoms (and thus correlate with them). Since clustering is essentially determined by a covariance structure amongst symptoms, it is understandable that symptoms that interact with many others will be related to many others (rather than related mostly to itself). Accordingly, we prefer not to speculate on exactly how the predictability of outcomes would relate to within-cluster homogeneity.
eFigure 9 -Silhouette analysis of main 12-item clustering.
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Supplementary efficacy analysis results
Dose-dependent effects of duloxetine on symptom cluster trajectories As described in the main manuscript, preliminary analyses of the four duloxetine doses on each cluster indicated that 120mg and 80mg doses per day were not significantly different from each other but differed from the lower doses and placebo. The 60mg and 40mg duloxetine doses were similar to each other and nearly indistinguishable from placebo. We therefore grouped cohorts into high dose duloxetine (80-120mg/day) and low dose duloxetine (40-60mg/day). For completeness, we also include the dose-dependence curves (model-fitted trajectories) to illustrate the effect of duloxetine dose on each symptom cluster (eFigure 10).
The slope estimates were as follows: To interpret the magnitude of differences between drugs, we calculate an effect size (ES), measured in raw rating scale points, that reflects the difference between treatments in reducing the overall severity of a symptom cluster. To calculate the effect size, we multiplied each slope contrast by the natural log of treatment duration, and multiplied it by the number of symptoms in each cluster. For example, in this study, high-dose duloxetine was significantly better than escitalopram at treating atypical symptoms, such that patient's total improvement in atypical severity was on average 1.9 HAM-D points greater on high-dose duloxetine than escitalopram (ES = 1.9, 95% CI = [1. 4, 2.3] , FDR corrected p<0.0003).
All effect sizes for slope contrasts are presented below, along with upper and lower bounds of the 95% confidence interval, for the two analyses. Figure 3 in the main manuscript illustrates the pattern of cross-trial (external validation) performance for these three symptom cluster models.
eTable9. Performance of a Simplified Analysis Pipeline (Combined Elastic Net and GLM) in STAR*D During
Repeated 10-fold Cross validation. These models performed similarly to the GBM pipeline in terms of RMSE and R 2 in the STAR*D cohort.
Supp. Table 9 Core Supplementary machine learning discussion (following from main manuscript)
It remains unclear why our original predictive modeling pipeline did not generalize well for cluster-level outcomes. It is possible that modeling cluster-level outcomes may be more susceptible to issues of inductive bias, since the selection of any machine learning algorithm necessarily introduces a bias in the types of associations (e.g. linear, non-linear) that can be learned. In line with this, we found that a modified pipeline using a less complex model generalized better for all three symptom clusters, but was no longer specific to predicting outcomes for treatments with similar pharmacological mechanism (eFigure 11). Although it was not the focus of the present study, it remains possible that once outcomes are decomposed into symptom clusters, certain symptom profiles will be predicted to have certain outcomes regardless of treatment intervention. Alternatively, cluster-level outcomes may be less reliable (and thus harder to predict), or require a greater volume of training data in order to learn reliable relationships between information observable at baseline and outcomes.
Clinical decision support implementation
A key factor in the uptake of clinical decision support tools is their accessibility. With this in mind, we will release a clinical decision support tool to help translate these findings into practice alongside the present manuscript. From the patients perspective, they will be able to complete a brief questionnaire from any web-browser (dynamically resized according to the device used). The device will return a brief report providing some insight into their symptom profile, and recommend treatments that are maximally effective in treating their worst symptom cluster. The patient's symptoms will also be benchmarked to broader distributions of symptoms observed in these and other data sets, in order to give the patient and the clinician a sense of how severe their symptoms are in each cluster relative to the broader population (returned as a percentile score).
In combination, this tool may offer an additional source of information for clinicians when they select an antidepressant medication, that they can integrate along with other clinical concerns (e.g. side effects, medication tolerability, drug-drug interactions, and patient preference). Some elements of the report are "fully personalized" to the individual patient (e.g. predictions of overall efficacy for citalopram and escitalopram), while others are based on group level effects of various treatments on different symptom clusters. This does still afford some level of "personalization", to the extent that medications can be selected by first identifying the most problematic symptom cluster for a patient, and then next recommending medications according to the best group-level improvement observed for that symptom cluster. In addition, other elements of peer reviewed literature are included in the report, including elements of treatment guidelines from the American Psychiatric Association and the British Association of Psychopharmacology, and results of formal meta-analyses that are already published.
The questionnaire is implemented in Ruby on Rails, and hosted on a cloud-based server that is encrypted-at-rest and fully HIPAA 
